Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is positioned to see strong growth in its core markets, with a large and growing membership base and high retention rates. This, combined with the utilization of its proprietary technology platform, Clover Assistant, has the potential to drive improved unit economics and profitability in the coming years. While there are potential headwinds in 2027, including a return to being paid as a 3.5-star plan and flat CMS rates, Clover's strong performance and track record of profitability make us optimistic about its future prospects. Our analysis suggests that the stock is currently undervalued and we maintain a BUY rating with a revised price target of $3.20.

Bears say

Clover Health Investments is facing multiple headwinds in the coming years, including a potential decrease in CMS MA advance rates and a shift to being paid as a 3.5-star plan. Despite management's focus on technology-driven improvements and cost containment, it is uncertain if the company can continue to profitably absorb a large new member cohort in 2026. However, strong retention rates in geographies with high Clover Assistant adoption could bode well for the company's financial performance. Additionally, potential regulatory changes to Medicare Advantage and Direct Contracting could negatively impact sentiment and profitability.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.